Drug recall · July 8, 2026
Gemcitabine Injection recall
Why: Temperature Abuse: Product was stored incorrectly in a controlled room temperature environment instead of a refrigerated environment.
Class II: could cause temporary or reversible health problems; serious harm is remote.
The recall
- Product
Gemcitabine Injection, 1 g per 26.3 mL (38 mg/mL), 26.3 mL Single-Dose Vial, For Intravenous Infusion ONLY, Rx only, Manufactured by: THYMOORGAN PHARMAZIE GmbH, Schiffgraben 23, 38690 Goslar, Germany; Distributed by: Hikma, Berkeley Heights, NJ 07922. NDC: 0143-9341-01
- Lots / codes
Lot #: CB0046, Exp. Date 06/2027
- Quantity
- 74 units
- Company
- McKesson, Irving, TX
- Distribution
- Nationwide within the United States
- Initiated
- June 10, 2026 · Voluntary: Firm initiated
- Classified
- July 21, 2026
- Reported
- July 8, 2026
- How notified
- Telephone
The drug: prices, other makers, shortages
If you have this product
- Check the lot number on your package against the lots above. Only those lots are recalled.
- Don't stop a prescription medicine on your own. Call your pharmacy - they can swap it for an unaffected lot or another maker.
- Felt unwell? Contact your doctor, and report it to FDA MedWatch (1-800-FDA-1088 or fda.gov/medwatch).
- Return or dispose of recalled product as the company or your pharmacy advises.
Questions about this recall
No comments yet. Questions, tips, what worked for you - start the conversation.
Watch Gemcitabine
One email when the price moves, a recall or shortage is posted, or the label changes. Plus the monthly biggest-movers report. Unsubscribe in one click.